Anti-TFF3, clone TFF-286

ELISA Analysis: A representative lot detected TFF3 in ELISA applications (Khummuang. S., et. al. (2017). Biol Proced Online. 19:14).

Western Blotting Analysis: A representative lot detected TFF3 in Western Blotting applications (Khummuang. S., et. al. (2017). Biol Proced Online. 19:14).

ELISA Western Blotting

Anti-TFF3, clone TFF-286, Cat. No. MABS2053, is a mouse monoclonal antibody that detects Trefoil factor 3 (TFF3) and has been tested for use in ELISA and Western Blotting.

Clone TFF-286 is a mouse monoclonal antibody that detects human Trefoil factor 3 (TFF3).

Recombinant human dimeric TFF3.

Stable for 1 year at 2-8°C from date of receipt.

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Evaluated by Western Blotting in recombinant Human Trefoil Factor-3, expressed in E. coli.

Western Blotting Analysis: 2 µg/mL of this antibody detected His-and Thioredoxin tagged recombinant human TFF3.

Trefoil factor 3 (UniProt: Q07654; also known as TFF3, Intestinal trefoil factor, hITF, Polypeptide P1.B, hP1.B) is encoded by the TFF3 (also known as ITF, TFI) gene (Gene ID: 7033) in human. TFF3 is a small soluble peptide secreted by mucin-producing intestinal epithelial cells and goblet cells. It is also expressed in the uterus, breast, and in some parts of the hypothalamus and pituitary gland. TFF3 is synthesized with a signal peptide (aa 1-35), which is subsequently cleaved off to produce the mature form. It can exist as a monomer or disulfide-linked homodimer. Upon dimerization, the additional 3(10)-helix involving residues 53-55 occur in the TFF3 homodimer that contributes to its distinct structure. The monomeric form is shown to induce cell migration by activating the MAPK pathway independently of the epidermal growth factor and the homodimeric form is shown to have an anti-apoptotic effect on epithelial cells. TFF3 is reported to promote mucosal wound healing in mice and humans and its elevated expression has been linked with gastric adenocarcinoma progression and biliary diseases. TFF3 expression in the intestine is shown to be regulated by food intake and its overexpression is shown to improve glucose tolerance by blocking the expression of gluconeogenic enzymes. TFF3 treatment in animals is reported to reduce fasting insulin levels. (Ref.: Xue, Y., et al. (2013). PLoS One. 8(9); e75240; Ge, H., et al. (2015). PLoS One. 10(6); e0126924; Khummuang, S., et al. (2017). Biological Procedures Online (2017) 19;14).

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.